Browsing: CAS Mwangangi

Health Chief Administrative Secretary (CAS), Dr Mercy Mwangangi.

According to data availed by the ministry of health, Dolutegravir (DTG) based regimens have high potency, a high genetic barrier to HIV drug resistance, low toxicity, and have fewer drug-to-drug interactions. 

It says that the availability of DTG 50mg film-coated tablets will foster improved adherence among the Children and Adolescents Living with HIV thereby improving treatment outcomes in children and adolescents.

“Evidence supports using DTG as a preferred First line ARV drug for Children and adolescents living with HIV with approved dosing and people co-infected with TB. The donation today adds an impetus to ensure that no child or adolescent living with HIV and has been transitioned to DTG as their current regimen, misses their drugs,” she added.